HER2 is a receptor protein that sits on the surface of cells throughout the body, where it helps relay signals that tell cells when to grow, divide, and survive. Encoded by the ERBB2 gene, it belongs to a four-member family of epidermal growth factor receptors that collectively orchestrate much of the cell-to-cell communication driving tissue development and maintenance. Most people encounter the name HER2 only in the context of breast cancer, but its everyday job in healthy tissue, particularly in the heart and during fetal development, is what makes it both biologically important and tricky to target with drugs.
Where HER2 Appears in Healthy Tissue
HER2 is not a cancer-specific protein. In normal adults, it is found on the membranes of epithelial cells lining the gastrointestinal tract, lungs, urinary tract, reproductive organs, skin, and breast tissue, among other sites.1PubMed. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues The protein is present at modest levels in these tissues, and the gene is not amplified; cells simply produce enough HER2 to participate in normal signaling. Fetal tissues tend to express higher amounts of HER2 than their adult counterparts, which makes sense given the rapid cell growth and organ formation happening before birth.1PubMed. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Among adults, the level of HER2 expression varies from person to person and from one cell type to another.2PubMed. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues
The point worth emphasizing is that HER2 is a normal part of cell biology. When researchers and oncologists talk about HER2-positive cancer, they are describing tumors in which the protein is wildly overproduced, not tumors that invented a protein from scratch. The normal baseline is a thin layer of HER2 molecules dotting the surface of cells that line your organs, doing their signaling work quietly.
How HER2 Sends Its Signals
HER2 is sometimes called an “orphan receptor” because, unlike the other three members of its receptor family (EGFR/HER1, HER3, and HER4), no one has identified a natural molecule that directly binds and activates it. Instead, HER2 works primarily as a partner. It pairs up with the other family members to form two-receptor complexes called dimers, and these dimers are what actually fire the downstream growth signals inside the cell.
The structure of HER2 helps explain why it is such an eager partner. Crystallography studies show that HER2’s extracellular region is locked in an open, “ready to pair” shape, with a binding pocket in its second structural domain exposed at all times.3Cancer Cell. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex The other receptors need to bind a growth factor before they shift into that shape. HER2 skips that step, which is why it is the preferred dimerization partner for the whole family. Recent live-cell imaging work has confirmed that HER2 does not tend to pair with copies of itself under normal conditions; rather, it forms partnerships with HER3 or HER4, sometimes even without a ligand present to trigger the pairing.4bioRxiv. HER4 is a high affinity dimerization partner for all EGFR/HER/ErbB-family proteins
Once a HER2-containing dimer forms, the intracellular portion of HER2 fires off signals through two major cascades. One is the PI3K/AKT pathway, which promotes cell survival and growth. The other is the RAS/RAF/MAPK pathway, which drives cell proliferation and differentiation.5PubMed Central. Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer In healthy tissue, these signals are tightly regulated. Cells receive a measured instruction to grow or survive, carry it out, and then the signal winds down. Trouble starts when the volume gets stuck at full blast.
HER2 in Embryonic and Cardiac Development
Some of the strongest evidence for HER2’s normal function comes from experiments where the gene was knocked out entirely. In mice engineered to lack the ERBB2 gene, embryos die before day 11 of gestation due to a severe defect in the heart’s trabecular structures, the muscular ridges that give the developing ventricles their pumping strength.6PubMed. Essential roles of Her2/erbB2 in cardiac development and function The same knockout embryos also fail to develop certain cranial sensory neurons that arise from neural crest cells. Without HER2, these critical developmental programs simply do not proceed.
Even after the heart finishes forming, HER2 remains important. A signaling molecule called neuregulin-1 (NRG-1), released by the endothelial cells that line blood vessels in the heart, binds to HER4 on cardiomyocytes. HER4 then partners with HER2 to activate downstream survival signals. This NRG-1/HER2/HER4 pathway stabilizes the structural proteins of the heart muscle, supports mitochondrial energy production, and suppresses cell death programs. In mice with HER2 selectively deleted only in heart muscle cells, the animals developed dilated cardiomyopathy, with thinning walls and weakened contractions.7PubMed Central. Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment? They were also far more vulnerable to the toxic effects of anthracycline chemotherapy drugs.8Mayo Clinic Proceedings. Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads In other words, HER2 acts as a guardian of heart muscle health, buffering cardiomyocytes against stress.
When HER2 Goes Wrong
The cancer connection arises when the ERBB2 gene is amplified, meaning cells carry many extra copies and churn out far more HER2 protein than normal. With so much receptor crowding the cell surface, HER2 molecules begin pairing with each other in large numbers, something that barely happens at normal expression levels. These HER2-HER2 homodimers fire continuously without needing any external growth factor, flooding the cell with pro-growth and pro-survival signals.9PubMed Central. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B The result is runaway cell division and resistance to normal cell death, two hallmarks of cancer.
HER2 amplification or overexpression has been documented across a range of tumor types. It is best known in breast cancer, where roughly one in five tumors are classified as HER2-positive, but it also occurs in gastric, colorectal, bladder, lung, and other cancers.10PubMed Central. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy In colorectal cancer, for instance, HER2 overexpression appears in a small but clinically meaningful fraction of cases. A large analysis of over 3,200 patients across three UK clinical trials found HER2 protein overexpression in about 2% of stage IV tumors and about 1% of stage II–III tumors, with nearly all overexpressing cases showing gene amplification on confirmatory testing.11PubMed Central. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials This matters because identifying HER2-driven cancers across different tissue types opens the door to existing HER2-targeted drugs.
Beyond gene amplification, HER2 overexpression can also expand the population of cells that behave like stem cells within a tumor. When researchers increased HER2 levels in normal mammary epithelial cells in the lab, the proportion of cells with stem-like characteristics rose. The same effect was seen in breast cancer cell lines, where the HER2-overexpressing stem-like population showed increased invasiveness and a greater ability to form tumors when implanted in mice.12Oncogene. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion This suggests that HER2 does not just push existing cancer cells to multiply faster; it also helps sustain the subset of cells most responsible for tumor growth and spread.
Shedding and Circulating HER2 Fragments
HER2 does not always stay anchored in the membrane. Enzymes on the cell surface can clip the protein’s extracellular portion, releasing it into the bloodstream. This process, called shedding, produces two pieces: a soluble fragment that can be measured in blood serum, and a truncated 95-kilodalton stub (known as p95-HER2) that remains embedded in the membrane.13PubMed. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer The leftover stub is constitutively active, meaning it fires growth signals nonstop without needing a partner or ligand.
From a clinical perspective, circulating HER2 fragments in the blood have been investigated as a potential biomarker for monitoring treatment response and disease progression. The metalloproteinase-driven cleavage that produces these fragments can be inhibited in the lab, which has fueled interest in blocking shedding as a complementary therapeutic strategy.14PubMed. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells The p95 fragment also poses a practical problem for treatment, because drugs like trastuzumab work by binding to the extracellular portion of HER2. If that portion has already been clipped off, the drug has nothing to grab onto, yet the remaining stub continues to signal.
How HER2 Status Is Measured
Determining whether a tumor is HER2-positive is one of the most consequential tests in oncology, because it dictates whether a patient is eligible for HER2-targeted therapies. The standard approach starts with immunohistochemistry (IHC), which stains a tumor tissue sample to reveal how much HER2 protein is present on cell surfaces. Results are scored on a four-tier scale: 0 and 1+ are considered negative, 3+ is positive, and 2+ is an ambiguous middle ground that requires a follow-up test.15Frontiers in Oncology. Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues That follow-up is typically fluorescence in situ hybridization (FISH), which counts the actual number of ERBB2 gene copies in the tumor cells to confirm whether the gene is amplified.
These testing methods have been in use for decades but continue to evolve. The arrival of newer antibody-drug conjugates like trastuzumab deruxtecan, which has shown activity even in tumors with low levels of HER2 expression (the so-called HER2-low category), has pushed pathologists to reconsider how finely they grade HER2 levels.16PubMed Central. HER2 testing: evolution and update for a companion diagnostic assay A tumor once dismissed as HER2-negative may now be reclassified as HER2-low and become eligible for treatment, making accurate scoring at the lower end of the scale more important than it used to be.
Why Blocking HER2 Can Harm the Heart
Understanding HER2’s protective role in cardiac muscle explains one of the best-known side effects of HER2-targeted cancer therapy. Trastuzumab, the pioneering antibody drug, works by binding HER2’s extracellular domain on tumor cells, blocking dimerization and flagging cells for immune destruction. But the drug cannot distinguish between HER2 on a cancer cell and HER2 on a cardiomyocyte. By blocking HER2 on heart muscle cells, trastuzumab disrupts the NRG-1 protective signaling pathway described earlier, leaving cardiomyocytes more vulnerable to stress.17PubMed Central. HER2-Targeted Therapy-From Pathophysiology to Clinical Manifestation: A Narrative Review
The downstream consequences include reduced activation of ERK1/2, which normally stabilizes the structural framework of heart muscle fibers, and diminished AKT signaling, which supports mitochondrial energy production. Together, these losses can trigger apoptosis in cardiomyocytes and lead to reduced pumping ability. When trastuzumab is given after anthracycline chemotherapy, which independently damages heart cells, the combination amounts to a “dual hit”: the anthracycline injures cardiomyocytes, and trastuzumab removes the NRG-1 repair pathway that would normally help them recover.18PubMed Central. Trastuzumab-induced cardiac dysfunction: A ‘dual-hit’ Trastuzumab can also amplify oxidative stress by interacting with angiotensin II-driven pathways that increase reactive oxygen species production in heart cells.
The good news, from a clinical standpoint, is that trastuzumab-related cardiac dysfunction is usually reversible once the drug is stopped, unlike the permanent damage anthracyclines can cause. This distinction is consistent with HER2’s role as a stress-response guardian rather than a structural building block: remove the blockade and the signaling pathway restarts.
How Cancers Learn to Work Around HER2-Targeted Drugs
Even in tumors that are clearly HER2-driven, resistance to HER2-targeted therapy is a persistent clinical problem. The mechanisms are varied and often stack on top of each other. One common escape route involves changes to the receptor itself. The p95 truncated form mentioned in the shedding section is one example: because it lacks the extracellular domain where trastuzumab binds, tumors dominated by p95-HER2 are inherently resistant. Separately, mucin-4 and other bulky cell-surface proteins can physically block trastuzumab from reaching HER2.19Nature Clinical Practice Oncology. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Cancer cells also reroute their growth signals. If trastuzumab shuts down HER2, some tumors ramp up alternative receptors like the insulin-like growth factor 1 receptor, which can cross-talk with HER2-family members and keep the PI3K/AKT cascade humming.19Nature Clinical Practice Oncology. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer Loss of the tumor suppressor PTEN, which normally acts as a brake on AKT signaling, produces a similar effect: the growth pathway stays active even though HER2 itself is blocked. More broadly, resistance can arise from downstream reactivation of signaling, immune evasion, or sheer heterogeneity within the tumor, where some cells are HER2-high and others are not, meaning the drug kills only part of the population.20Advances in Cancer Biology – Metastasis. HER2-targeted therapy resistance in breast cancer: Molecular mechanisms, therapeutic evolution, and precision oncology approaches
Newer Drug Strategies and What They Reveal About HER2 Biology
The latest generation of HER2-targeted drugs reflects a deepening understanding of how the protein behaves on the cell surface. Antibody-drug conjugates like trastuzumab deruxtecan attach a potent chemotherapy payload to a trastuzumab-like antibody. Once the antibody locks onto HER2 and the whole complex is pulled inside the cell, the toxic payload is released internally, killing the cancer cell from within. The high drug-to-antibody ratio of trastuzumab deruxtecan, about eight drug molecules per antibody, means each internalization event delivers a concentrated dose.21Critical Reviews in Oncology/Hematology. Trastuzumab deruxtecan in breast cancer Because the payload can also diffuse into neighboring cells, even HER2-low tumors that would not respond to older antibodies can be affected.
Small-molecule inhibitors like tucatinib add another layer. Tucatinib works inside the cell by blocking HER2’s enzymatic activity, but it also has an indirect effect on the cell surface. By preventing HER2 from being tagged for degradation, tucatinib keeps more HER2 molecules available on the membrane. When combined with an antibody-drug conjugate, this means more targets for the antibody to latch onto, more internalization events, and ultimately a higher intracellular concentration of the cytotoxic payload.22PubMed Central. HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer This approach essentially weaponizes the cell’s own protein-recycling machinery against itself.
The Evolutionary Roots of the HER2 Family
HER2 did not appear out of nowhere. Phylogenetic analysis of the four-member ErbB receptor family across 27 vertebrate species suggests that all four receptors arose through ancient gene duplication events, then diverged in function under a combination of purifying selection, which preserves critical activity, and bursts of positive selection, which allowed new functional specialization.23Genomics. Natural selection and functional diversification of the epidermal growth factor receptor EGFR family in vertebrates HER2’s unique structural feature, an extracellular domain that is permanently in the active conformation, appears to be the product of this divergence. The result is a receptor that cannot be switched on by a ligand because it is always on, ready to amplify signals initiated by its siblings. In evolutionary terms, the receptor family gained flexibility by dedicating one member to the role of obligate co-receptor, always available for partnership, while the others retained ligand-dependent regulation.